Dynavax Technologies Co. (DVAX) Expected to Post Earnings of -$0.58 Per Share
Wall Street analysts expect Dynavax Technologies Co. (NASDAQ:DVAX) to announce earnings of ($0.58) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Dynavax Technologies’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.56). Dynavax Technologies posted earnings per share of ($0.38) during the same quarter last year, which indicates a negative year over year growth rate of 52.6%. The business is expected to issue its next earnings report on Friday, November 2nd.
On average, analysts expect that Dynavax Technologies will report full-year earnings of ($2.39) per share for the current year, with EPS estimates ranging from ($2.42) to ($2.33). For the next fiscal year, analysts expect that the business will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.70) to ($1.23). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01). The company had revenue of $1.25 million during the quarter, compared to analysts’ expectations of $1.88 million. Dynavax Technologies had a negative return on equity of 72.31% and a negative net margin of 8,570.06%. The business’s quarterly revenue was up 1094.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.41) EPS.
Several institutional investors have recently bought and sold shares of DVAX. Tiverton Asset Management LLC purchased a new stake in Dynavax Technologies during the 2nd quarter valued at $184,000. WINTON GROUP Ltd purchased a new stake in Dynavax Technologies during the 1st quarter valued at $199,000. Xact Kapitalforvaltning AB purchased a new stake in Dynavax Technologies during the 1st quarter valued at $200,000. Commonwealth Equity Services LLC purchased a new stake in Dynavax Technologies during the 1st quarter valued at $212,000. Finally, Bank of Montreal Can boosted its stake in Dynavax Technologies by 365.4% during the 2nd quarter. Bank of Montreal Can now owns 13,938 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 10,943 shares during the last quarter. Institutional investors own 82.02% of the company’s stock.
Shares of Dynavax Technologies stock traded down $0.30 during midday trading on Thursday, hitting $12.10. The company had a trading volume of 585,800 shares, compared to its average volume of 1,358,197. The company has a quick ratio of 8.67, a current ratio of 8.87 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $776.43 million, a P/E ratio of -7.08 and a beta of 0.24. Dynavax Technologies has a 52-week low of $11.35 and a 52-week high of $24.45.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.